Activating the lipid-sensing transcription factor peroxisome proliferator-activated receptor delta (PPARδ) promoted cancer-cell growth but strengthened tumor-fighting immune cells when activated in a different cellular compartment, according to a study published October 14, 2026, in Nature Immunology. Researchers led by Paul Bunk, Ilgin Ergin and colleagues used genetically modified mouse tumors, immune-cell experiments and engineered human T cells to show that the consequences of activating the same molecular pathway depend on which cells receive the signal.
Activating PPARδ in cancer cells and immune cells produced opposing results
Peroxisome proliferator-activated receptor delta (PPARδ), also called PPARβ/δ, is a transcription factor that responds to lipid-related signals and helps regulate the genes cells use to process energy. It operates in several tissues, including cancers and the immune cells that attempt to destroy them. Previous experiments have produced apparently conflicting conclusions about whether stimulating this pathway encourages or suppresses cancer.
The new work tested a specific explanation for that conflict: the effect may depend on the cellular compartment. The researchers engineered a version of PPARδ with enhanced activity and expressed it separately in cancer cells or in immune cells. They first evaluated mouse colorectal tumors derived from the MC38 cell line. When PPARδ was activated in tumor cells alone, tumor growth increased. When activated in immune cells, tumors were suppressed, including tumors whose cancer cells also had activated PPARδ.
That distinction matters because a drug that activates a molecular pathway throughout the body could affect tumor cells and immune cells simultaneously. Improving the capacity of immune cells does not automatically make broad systemic activation safe. The investigators’ experiments instead suggest that selective targeting of immune cells could be more useful than treating PPARδ as uniformly beneficial or harmful.
PPARδ made tumor-infiltrating CD8 T cells more effective
To investigate why tumors behaved differently, the team examined immune cells within the tumor microenvironment. CD8-positive T cells are a central component of the body’s response to malignant cells, but persistent exposure to tumor-associated signals can impair their ability to expand and kill. Related work has examined MEK signaling and T-cell exhaustion as another way to understand this dysfunction.
Using single-cell RNA sequencing and assays of chromatin accessibility, the investigators found that immune-cell PPARδ activation shifted the program of tumor-infiltrating T cells. Their cells showed changes associated with immune recognition, cytotoxic activity and transcriptional accessibility at effector-associated genes. In contrast, tumors with PPARδ activated only in cancer cells fostered immune-cell states with more expression and accessibility of dysfunction-associated genes.
These measurements characterize how cells behaved within experimental tumors. They do not establish that patients with more PPARδ activity in their T cells will survive longer, and they do not identify a clinically validated biomarker or dose for changing the pathway.
Fatty-acid oxidation contributed to the stronger immune response
The authors linked the enhanced T-cell activity to cellular metabolism. Fatty-acid oxidation is the process by which cells break down fatty acids to generate energy and metabolic intermediates. PPARδ increased this activity in CD8 T cells through a pathway involving carnitine palmitoyltransferase 1A (CPT1A), a protein involved in transporting long-chain fatty acids for mitochondrial oxidation.
Metabolic profiling, measurements of oxygen consumption and experiments tracing the breakdown of labeled fatty acids supported this mechanism. When the researchers genetically disrupted Cpt1a, they impaired the increase in fatty-acid oxidation associated with PPARδ activation. They also observed changes in fatty-acid distribution inside tumors that were consistent with enhanced nutrient competition by activated immune cells.
The proposed mechanism is more specific than a claim that immune cells simply need more energy. PPARδ altered both metabolism and the accessibility of genomic regions involved in immune-cell function. The work therefore describes a coordinated metabolic and transcriptional program. It also leaves questions about which of these changes are essential in different cancers and whether the same balance occurs in human tumors.
Immune-cell PPARδ activation improved responses in hard-to-treat mouse colorectal tumors
A clinically important aspect of the research concerns microsatellite-stable (MSS) metastatic colorectal cancer. Most colorectal cancers are MSS or mismatch repair-proficient. Unlike the mismatch repair-deficient tumors that can respond dramatically to checkpoint inhibitors, MSS tumors frequently resist existing immunotherapies.
The researchers tested models designed to reproduce important features of this resistance. Immune-cell PPARδ activation increased tumor control and made experimental MSS metastatic colorectal cancer more responsive to immune checkpoint blockade in mice. That offers a different strategy from using a checkpoint drug alone: strengthen the immune cells attempting to act within the tumor, rather than only removing signals that restrain them.
The difference between MSS and mismatch repair-deficient colorectal cancer is important when interpreting the recent FDA approval of dostarlimab for selected rectal cancers. That approval concerns a molecularly defined mismatch repair-deficient population. The new PPARδ findings do not expand that approval or show that the same treatment works in MSS disease.
Engineering human CAR-T cells provided another preclinical test
The team also investigated chimeric antigen receptor T cells (CAR-T cells), immune cells engineered to recognize specific tumor targets. CAR-T therapies have already transformed treatment for some blood cancers, but solid tumors pose persistent challenges, including restricted infiltration, nutrient competition and immune suppression. Bites of Bio previously covered an experimental CAR-T strategy for solid tumors.
In the new study, pharmacological or genetic PPARδ activation enhanced several measures of engineered human CAR-T-cell function in laboratory experiments. Investigators reported stronger fatty-acid oxidation, shifts toward genes associated with effector activity and changes in chromatin accessibility. Genetically modified human CAR-T cells also controlled established SK-OV-3 tumors more effectively than comparison CAR-T cells in immunodeficient mice.
These experiments incorporated human cells, but they were not treatment trials in people. Tumor-bearing mice given engineered human cells cannot reproduce the complete immune systems, tumor diversity and potential toxicities of patients receiving experimental cell therapy.
What the evidence cannot yet answer
The study provides mechanistic evidence from multiple models, but several uncertainties stand between these findings and patient care. First, most tumor-response experiments were conducted in mice. Results may differ across human cancers and across immune-cell populations inside individual tumors. Second, experimental genetic activation is not interchangeable with delivering a safe, selectively targeted medication to a patient. A systemic PPARδ activator could also stimulate cancer-cell pathways that the experiments identify as potentially harmful.
Third, enhanced CAR-T function in culture or mouse xenografts is not evidence of improved response rates, survival or safety in human clinical trials. Selective delivery to immune cells, durability of the metabolic state, effects on other tissues and possible unintended immune reactions all require evaluation. The study does not provide a patient treatment schedule or support self-directed use of PPARδ-activating compounds.
The work received support including grants from the US National Cancer Institute and several foundations. The article reports that multiple authors are inventors on a patent application concerning metabolic activation of immune cells to enhance antitumor immunity. Senior author Semir Beyaz also disclosed unrelated industry research support and an advisory/cofounder role; other authors reported additional commercial relationships related to cellular therapy. These disclosures are relevant to evaluating future translational claims, although they do not by themselves invalidate the experiments.
Selective activation, rather than pathway-wide stimulation, is the therapeutic question
What emerges from the experiments is not a paradoxical cancer drug ready for patients, but a testable strategy: exploit the metabolic requirements of antitumor T cells without enhancing the same program in malignant cells. Future work will need to demonstrate selective delivery, meaningful benefits in clinically relevant human tumor systems and an acceptable safety profile before PPARδ manipulation can be considered a treatment approach.
References
- Bunk P, Ergin I, Maher T, et al. Compartment-specific PPARδ activity controls the outcome of cancer–immune cell competition and immunotherapy efficacy. Nature Immunology. Published October 14, 2026. DOI: 10.1038/s41590-026-02685-2.